Search Results - "LAPUERTA, PABLO"

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure by Bhatt, Deepak L, Szarek, Michael, Steg, P. Gabriel, Cannon, Christopher P, Leiter, Lawrence A, McGuire, Darren K, Lewis, Julia B, Riddle, Matthew C, Voors, Adriaan A, Metra, Marco, Lund, Lars H, Komajda, Michel, Testani, Jeffrey M, Wilcox, Christopher S, Ponikowski, Piotr, Lopes, Renato D, Verma, Subodh, Lapuerta, Pablo, Pitt, Bertram

“…Patients with diabetes and recent worsening heart failure that had led to hospitalization were randomly assigned to receive sotagliflozin or placebo. At a…”
Get full text

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease by Bhatt, Deepak L, Szarek, Michael, Pitt, Bertram, Cannon, Christopher P, Leiter, Lawrence A, McGuire, Darren K, Lewis, Julia B, Riddle, Matthew C, Inzucchi, Silvio E, Kosiborod, Mikhail N, Cherney, David Z.I, Dwyer, Jamie P, Scirica, Benjamin M, Bailey, Clifford J, Díaz, Rafael, Ray, Kausik K, Udell, Jacob A, Lopes, Renato D, Lapuerta, Pablo, Steg, P. Gabriel

“…In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes,…”
Get full text

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor by Lapuerta, Pablo, Zambrowicz, Brian, Strumph, Paul, Sands, Arthur

“…The sodium-dependent glucose transporter 2 (SGLT2) inhibitors are an important emerging class for the treatment of diabetes. Development of SGLT2 inhibitors…”
Get more information

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome by Kulke, Matthew H, Hörsch, Dieter, Caplin, Martyn E, Anthony, Lowell B, Bergsland, Emily, Öberg, Kjell, Welin, Staffan, Warner, Richard R P, Lombard-Bohas, Catherine, Kunz, Pamela L, Grande, Enrique, Valle, Juan W, Fleming, Douglas, Lapuerta, Pablo, Banks, Phillip, Jackson, Shanna, Zambrowicz, Brian, Sands, Arthur T, Pavel, Marianne

“…Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with…”
Get full text

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes by Sands, Arthur T, Zambrowicz, Brian P, Rosenstock, Julio, Lapuerta, Pablo, Bode, Bruce W, Garg, Satish K, Buse, John B, Banks, Phillip, Heptulla, Rubina, Rendell, Marc, Cefalu, William T, Strumph, Paul

“…To assess the safety and efficacy of dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1…”
Get full text

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial by Pavel, Marianne, Gross, David J, Benavent, Marta, Perros, Petros, Srirajaskanthan, Raj, Warner, Richard R P, Kulke, Matthew H, Anthony, Lowell B, Kunz, Pamela L, Hörsch, Dieter, Weickert, Martin O, Lapuerta, Pablo, Jiang, Wenjun, Kassler-Taub, Kenneth, Wason, Suman, Fleming, Rosanna, Fleming, Douglas, Garcia-Carbonero, Rocio

“…Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome…”
Get full text

Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy by Vaduganathan, Muthiah, MD, MPH, Bhatt, Deepak L., MD, MPH, Cryer, Byron L., MD, Liu, Yuyin, MS, Hsieh, Wen-Hua, PhD, Doros, Gheorghe, PhD, Cohen, Marc, MD, Lanas, Angel, MD, DSc, Schnitzer, Thomas J., MD, PhD, Shook, Thomas L., MD, Lapuerta, Pablo, MD, Goldsmith, Mark A., MD, PhD, Laine, Loren, MD, Cannon, Christopher P., MD

“…Abstract Background The COGENT (Clopidogrel and the Optimization of Gastrointestinal Events Trial) showed that proton-pump inhibitors (PPIs) safely reduced…”
Get full text

Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey by Komajda, Michel, Lapuerta, Pablo, Hermans, Nancy, Gonzalez-Juanatey, José Ramon, van Veldhuisen, Dirk J., Erdmann, Erland, Tavazzi, Luigi, Poole-Wilson, Philip, Le Pen, Claude

“…Aims The impact on outcome of the implementation of European guidelines for the treatment of chronic heart failure (CHF) has not been evaluated. We…”
Get full text

Non-adherence to antipsychotic medication regimens: Associations with resource use and costs by Knapp, Martin, King, Derek, Pugner, Klaus, Lapuerta, Pablo

“…Several factors are thought to influence resource use and costs in treating schizophrenia. To assess the relative impact of non-adherence and other factors…”
Get full text

Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach by Gelhorn, Heather L., PhD, Kulke, Matthew H., MD, O’Dorisio, Thomas, MD, Yang, Qi M., PhD, Jackson, Jessica, BS, Jackson, Shanna, MBA, Boehm, Kristi A., MS, Law, Linda, MD, Kostelec, Jacqueline, BA, Auguste, Priscilla, MHS, Lapuerta, Pablo, MD

“…Abstract Purpose Telotristat etiprate, a tryptophan hydroxylase inhibitor, was previously evaluated in a Phase II randomized, placebo-controlled clinical trial…”
Get full text

LX4211 Therapy Reduces Postprandial Glucose Levels in Patients With Type 2 Diabetes Mellitus and Renal Impairment Despite Low Urinary Glucose Excretion by Zambrowicz, Brian, PhD, Lapuerta, Pablo, MD, Strumph, Paul, MD, Banks, Phillip, MS, FRS, Wilson, Alan, PhD, Ogbaa, Ike, MD, Sands, Arthur, MD, PhD, Powell, David, MD

“…Abstract Purpose We sought to assess the efficacy and safety profile of LX4211, a dual inhibitor of sodium-glucose cotransporter1 (SGLT1) and SGLT2, in…”
Get full text

Telotristat ethyl reverses myxomatous changes in mice mitral valves by Wang, Xinmei, Kuban-Johnston, Danielle, Lapuerta, Pablo, Lacerda, Carla M R

“…Myxomatous mitral valve degeneration is a common pathological manifestation of mitral valve regurgitation, with or without valvular prolapse. In addition to…”
Get full text

Walking speed predicts health status and hospital costs for frail elderly male veterans by Purser, Jama L, Weinberger, Morris, Cohen, Harvey J, Pieper, Carl F, Morey, Miriam C, Li, Tracy, Williams, G Rhys, Lapuerta, Pablo

“…This study evaluated the use of walking speed as an indicator of function and health status in acutely ill, hospitalized, older male veterans. Hospital…”
Get full text

Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome by Hudgens, Stacie, Ramage, John, Kulke, Matthew, Bergsland, Emily, Anthony, Lowell, Caplin, Martyn, Öberg, Kjell, Pavel, Marianne, Gable, Jonathon, Banks, Phillip, Yang, Qi Melissa, Lapuerta, Pablo

“…Background Carcinoid syndrome is associated with a reduced quality of life that can be attributed to symptoms such as diarrhea and fatigue as well as social…”
Get full text

Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease by Palmer, Andrew J, Annemans, Lieven, Roze, Stéphane, Lamotte, Mark, Lapuerta, Pablo, Chen, Roland, Gabriel, Sylvie, Carita, Paulo, Rodby, Roger A, de Zeeuw, Dick, Parving, Hans-Henrik

“…Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor…”
Get full text

129. The Effects of Novel Small Molecules in a Preclinical Model of Positive Affective State by Mohanty, Sarina, Roberts, Amanda, Levy, Daniel, Haggarty, Stephen, Lapuerta, Pablo

Get full text

The clinically meaningful change in physical performance scores in an elderly cohort by Nieves, Jeri W, Li, Tracy, Zion, Marsha, Gussekloo, Jacobijn, Pahor, Marco, Bernabei, Roberto, Simon, Henry, Williams, G Rhys, Lapuerta, Pablo

“…The aim of this study was to assess annual changes in the continuous summary physical performance score (CSPPS) and the quartile summary physical performance…”
Get full text

Economic analysis of inadequate symptom control in carcinoid syndrome in the United States by Burton, Tanya, Lapuerta, Pablo

“…We investigated the healthcare resource utilization and costs of patients with dose escalations beyond recommended levels of long-acting octreotide for…”
Get full text

Economic Analysis of  Inadequate Symptom Control in Carcinoid Cyndrome in the United States by Burton, Tanya, Lapuerta, Pablo

Get full text

Quality of care for hypertension in the United States by Asch, Steven M, McGlynn, Elizabeth A, Hiatt, Liisa, Adams, John, Hicks, Jennifer, DeCristofaro, Alison, Chen, Roland, LaPuerta, Pablo, Kerr, Eve A

“…Despite heavy recent emphasis on blood pressure (BP) control, many patients fail to meet widely accepted goals. While access and adherence to therapy certainly…”
Get full text